Xiangxue Pharmaceutical (300147) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.069x

Based on the latest financial reports, Xiangxue Pharmaceutical (300147) has a cash flow conversion efficiency ratio of 0.069x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥75.64 Million ≈ $11.07 Million USD) by net assets (CN¥1.10 Billion ≈ $160.78 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Xiangxue Pharmaceutical - Cash Flow Conversion Efficiency Trend (2007–2024)

This chart illustrates how Xiangxue Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Xiangxue Pharmaceutical balance sheet liabilities for a breakdown of total debt and financial obligations.

Xiangxue Pharmaceutical Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Xiangxue Pharmaceutical ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
BlackRock Credit Allocation Income Trust
NYSE:BTZ
0.039x
Dios Fastigheter AB
ST:DIOS
0.026x
Daheng New Epoch Technology Inc
SHG:600288
0.026x
Agesa Hayat ve Emeklilik AS
IS:AGESA
0.086x
KSB SE & Co. KGaA
F:KSB3
0.022x
Edgewell Personal Care Co
NYSE:EPC
-0.085x
BGT Group Co. Ltd.
SHE:300774
N/A
Arena REIT
AU:ARF
0.029x

Annual Cash Flow Conversion Efficiency for Xiangxue Pharmaceutical (2007–2024)

The table below shows the annual cash flow conversion efficiency of Xiangxue Pharmaceutical from 2007 to 2024. For the full company profile with market capitalisation and key ratios, see 300147 stock market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥1.44 Billion
≈ $210.55 Million
CN¥18.17 Million
≈ $2.66 Million
0.013x -88.91%
2023-12-31 CN¥2.31 Billion
≈ $338.50 Million
CN¥263.44 Million
≈ $38.55 Million
0.114x +41.15%
2022-12-31 CN¥2.82 Billion
≈ $412.39 Million
CN¥227.38 Million
≈ $33.27 Million
0.081x +17.71%
2021-12-31 CN¥3.76 Billion
≈ $549.88 Million
CN¥257.56 Million
≈ $37.69 Million
0.069x +13.35%
2020-12-31 CN¥4.25 Billion
≈ $622.35 Million
CN¥257.18 Million
≈ $37.63 Million
0.060x +199.49%
2019-12-31 CN¥4.11 Billion
≈ $601.66 Million
CN¥83.02 Million
≈ $12.15 Million
0.020x -11.21%
2018-12-31 CN¥4.01 Billion
≈ $587.12 Million
CN¥91.24 Million
≈ $13.35 Million
0.023x -19.37%
2017-12-31 CN¥3.88 Billion
≈ $568.31 Million
CN¥109.53 Million
≈ $16.03 Million
0.028x -47.65%
2016-12-31 CN¥3.68 Billion
≈ $539.14 Million
CN¥198.48 Million
≈ $29.04 Million
0.054x +19.47%
2015-12-31 CN¥3.55 Billion
≈ $518.89 Million
CN¥159.89 Million
≈ $23.40 Million
0.045x -49.04%
2014-12-31 CN¥1.87 Billion
≈ $273.82 Million
CN¥165.58 Million
≈ $24.23 Million
0.088x -53.92%
2013-12-31 CN¥1.71 Billion
≈ $250.23 Million
CN¥328.37 Million
≈ $48.05 Million
0.192x +148.14%
2012-12-31 CN¥1.54 Billion
≈ $224.85 Million
CN¥118.91 Million
≈ $17.40 Million
0.077x +271.56%
2011-12-31 CN¥1.42 Billion
≈ $207.64 Million
CN¥29.55 Million
≈ $4.32 Million
0.021x -37.21%
2010-12-31 CN¥1.37 Billion
≈ $200.56 Million
CN¥45.47 Million
≈ $6.65 Million
0.033x -75.75%
2009-12-31 CN¥337.62 Million
≈ $49.41 Million
CN¥46.19 Million
≈ $6.76 Million
0.137x -51.75%
2008-12-31 CN¥196.54 Million
≈ $28.76 Million
CN¥55.72 Million
≈ $8.15 Million
0.284x -60.67%
2007-12-31 CN¥191.45 Million
≈ $28.02 Million
CN¥138.02 Million
≈ $20.20 Million
0.721x --

About Xiangxue Pharmaceutical

SHE:300147 China Biotechnology
Market Cap
$969.59 Million
CN¥6.63 Billion CNY
Market Cap Rank
#9244 Global
#2494 in China
Share Price
CN¥10.02
Change (1 day)
+6.48%
52-Week Range
CN¥6.21 - CN¥11.74
All Time High
CN¥25.81
About

Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, production, and sales of modern Chinese medicine in China. The company provides ban lan gen granules, flu-over liquid, juhong cough-off liquid, and juhong cough-off decoction; chinese herbal, such as huazhou citri grandis, goji berry, chrysanthemum, and rose dried buds; beverages, including king sarsae, asia sarsae, diet s… Read more